[Changes of Serum Complement C1q in Patients with Multiple Myeloma]

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• The complement system, including C1q, plays a role in immune regulation and inflammation, potentially influencing MM pathogenesis.
• Understanding biomarkers associated with MM is crucial for diagnosis, prognosis, and treatment monitoring.

Purpose of the Study:

• To investigate the serum C1q levels in patients with multiple myeloma (MM).
• To analyze the correlation between C1q levels and clinical characteristics in MM patients.
• To evaluate the changes in C1q levels in response to MM treatment.

Main Methods:

• A cohort of 138 newly diagnosed MM patients was studied.
• Control groups included patients with anemia, lymphoma, leukemia, and myelodysplastic syndrome (MDS).
• Serum C1q levels were measured before and after treatment, and compared between MM patients and controls, as well as across different treatment response groups.

Main Results:

• Serum C1q levels were significantly lower in MM patients compared to control groups (P<0.01).
• Higher C1q levels in newly diagnosed MM patients correlated with better levels of white blood cell, platelet, hemoglobin, serum calcium, albumin, and lactate dehydrogenase.
• C1q levels increased significantly in MM patients achieving complete remission or very good partial remission after treatment (P<0.05).

Conclusions:

• Serum C1q is a potential biomarker for multiple myeloma, showing lower levels in MM patients compared to other hematologic diseases.
• C1q levels correlate with certain clinical characteristics and improve with treatment-induced disease remission.
• Further research into C1q's role may offer insights into MM management.